Additionally, the administration of Reolysin with paclitaxel and carboplatin resulted in a 30% improvement in the survival rate of patients with metastatic/recurrent NSCLC harboring KRAS mutations or EGFR mutations/amplifications [101]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.